Projects
NEURINOX
project name: NOX Enzymes As Mediators Of Inflammation-triggered Neurodegeneration: Modulating NOX Enzymes As Novel Therapies
Framework Programme: FP7 programme area: Health
contract/proposal/call number: 278611
status: active
start date: January 2012 duration: 60 months projected finish date: January 2017
Project Budget
total budget: € 15,444,503
Participants
Note that the follow people may not represent the full extent of the consortium. FEAST has tried to identify the Australian participants, and their collaborators (or coordinator), within the project. Also note that Australian participation may not necessarily be on a formal level. Further details about the partners in this project can be found at the website listed below.
| name | organisation | state or country |
|---|---|---|
| University of Geneva | Switzerland | |
| USyd | NSW, Australia |
Further information
WWW: cordis.europa.eu/search/index.cfm?fuseaction=proj.document&PJ_RCN=12702664
summary:
NEURINOX aims at elucidating the role of NADPH oxidases (NOX) in neuro-inflammation and its progression to neurodegenerative diseases (ND), as well as evaluating the potential of novel ND therapeutics approaches targeting NOX activity. NOX generate reactive oxygen species (ROS) and have emerged as regulators of neuro-inflammation. Their role is complex: ROS generated by NOX lead to tissue damage in microglia-mediated neuro-inflammation, as seen in amyotrophic lateral sclerosis (ALS), while absence of ROS generation enhances the severity of autoimmune-mediated neuro-inflammation, as seen for e.g. in multiple sclerosis (MS).
The objective of the 5 years NEURINOX project is to understand how NOX controls neuroinflammation, identify novel molecular pathways and oxidative biomarkers involved in NOX-dependent neuro-inflammation, and develop specific therapies based on NOX modulation. The scientific approach will be to:
(i) Identify NOX-dependent molecular mechanisms using dedicated ND animal models
(ii) Develop therapeutic small molecules either inhibiting or activating NOX and test their effects in animal models
(iii) Test the validity of identified molecular pathways in clinical studies in ALS and MS patients.
NEURINOX will contribute to better understand brain dysfunction, and more particularly the link between neuroinflammation and ND and to identify new therapeutic targets for ND. A successful demonstration of the benefits of NOX modulating drugs in ALS and MS animal models, and in ALS early clinical trials will validate a novel high potential therapeutics target for ALS and also many types of ND. NEURINOX has hence a strong potential for more efficient ND healthcare for patients and thus for reducing ND healthcare costs.
This multi-disciplinary consortium includes leading scientists in NOX research, ROS biology, drug development SMEs, experts in the neuro-inflammatory aspects of ND, genomics and proteomics, and clinicians able to translate the basic science to the patient.
